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Conclusion: Early post-prostatectomy salvage radiation 
before the PSA reaches 0.2 ng/mL results in superior bPFS 
compared to those treated later. This strongly suggests that a 
new definition of post-prostatectomy progression is needed. 
 













Did I do it right? What was the result? Process and 
outcomes in radiotherapy  




I am honoured to have been invited to give this memorial 
lecture for which there are three main criteria: it is firstly to 
honour Emmanuel van der Scheuren, one of the fathers of our 
society. Secondly it aims to recognise scientific work within 
the field of radiation oncology and thirdly a contribution to 
education through the ESTRO programmes, in which I have 
been privileged to participate for the last 30 years or so. 
The first ESTRO annual conference was held in London in 
1982 and was memorable with the preparations being agreed 
between Emmanuel and Mike Peckham, my boss at the Royal 
Marsden Hospital at the time. I also want to acknowledge 
how dependent we were on many others for support, 
particularly among others for Lea, of whom we are thinking 
with gratitude especially at this time. 
 Scientific breakthroughs usually build on work that others 
have done and there are many examples from within the field 
of radiation oncology which I have experienced particularly in 
my area of research into whole-body irradiation. We work 
with the unchanging laws of physics but technology advances 
all the time and new biological understanding and new agents 
impact on the way in which we practice oncology. 
 I will discuss some of the ways in which progress in 
radiotherapy may occur and consider the factors which 
determine the impact of clinical trials, with particular 
reference to the START trials run by John Yarnold and his 
team. Consensus guidance, such as that contained in the 
ICRU report 50, has changed practice but there is still much 
evaluation work to be done in some areas. In our activity 
currently, process sometimes seems to take precedence over 
everything else, without the evaluation which would validate 
it.  
ESTRO’s contribution to education has been enormous and it 
has been exciting to be involved in the teaching courses and 
publications of ESTRO with its ever-changing and innovative 
approaches .It is good to note that a new era is starting for 
the School. Amongst all the changes in current practice the 
needs of individual patients must remain our priority 
 
Symposium with Proffered Papers: Hot topics in SABR: time 




Do we need randomised clinical data to justify the use of 
SABR for primary and oligometastatic cancer? 
 
To be confirmed 
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Because the results obtained with stereotactic radiosurgery 
(SRS) and stereotactic ablative radiotherapy (SABR) have 
been impressive they have raised the question of whether 
classic radiobiological modeling are appropriate for large 
doses per fraction. In addition to objections to the LQ model, 
the possibility of additional biological effects resulting from 
endothelial cell damage and/or enhanced tumor immunity, 
have been raised to account for the success of SRS and SABR. 
However, the preclinical data demonstrate the following: 
1) Quantitative in vivo endpoints, including late responding 
damage to the rat spinal cord, acute damage to mouse skin 
and early and late damage to the murine small intestine, are 
consistent with the LQ model over a wide range of doses per 
fraction, including the data for single fractions of up to 20 
Gy. 
2) Data on the response of tumors to high single doses are 
consistent with cell killing at low doses. Thus the dose to 
control 50% of mouse tumors (the TCD50) can be predicted 
from cell survival curves at low doses and the number of 
clonogenic cells in the tumors. 
Further the clinical data show: 
3) The high local control of NSCLC and of brain metastases by 
SABR and SRS is the result of high radiation doses leading the 
high BED. In other words the high curability is predicted by 
current radiobiological modeling. 
4) Because high doses are required in SABR it is not possible 
to use it in all circumstances (e.g. for tumors close to critical 
normal structures). But because these high doses are needed 
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because of tumor hypoxia there is a major opportunity to 
improve SABR by the use of hypoxic cell radiosensitizers. 
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The technological developments in radiotherapy have had a 
considerable impact on the way stereotactic radiotherapy is 
delivered. Increased confidence, provided for example, by 
the wide availability of image guidance, has permitted more 
and more institutions to offer SABR as a treatment option. 
However, some characteristics of SABR plans such as 
heterogeneous dose prescription, can make the comparison 
between different institutions and different technological 
approaches very challenging. In this session, we will review 
the impact of image guidance strategies, dose calculation 
algorithms, and normalization guidelines on the planned dose 
distribution. We will also discuss how these technological 
aspects should influence how we look at clinical trials of the 
past, and what should be taken into account when designing 
new multi-centre trials. 
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Purpose or Objective: SBRT is highly effective in providing 
local control in selected patients with hepatic malignancies. 
However, various dosing and fractionation schemes with a 
wide range of toxicity end-points have been reported in the 
literature. The objective of this work was to review the 
normal tissue dose-volume effects for liver SBRT and derive 
normal tissue complication probability models. 
 
Material and Methods: A literature review by the AAPM 
Working Group on SBRT was performed. Twelve studies that 
contained both dose/volume and toxicity data from 541 
patients with hepatocellular carcinoma, intrahepatic 
cholangiocarcinoma, and/or liver metastases were identified 
and analyzed. Patients received a median total dose of 40 Gy 
(range 18-60 Gy) in 1-6 fractions. The 3 end-points that were 
chosen for pooled dose-response relationships analysis were 
grade 3+ (G3+) liver enzyme elevation as a function of mean 
liver dose (MLD), G2+ GI toxicity as a function of prescription 
(RX) or PTV dose, and G3+ GI toxicities as a function of 
RX/PTV dose. The RX/PTV doses were chosen because doses 
to specific OARs were not available in many instances. Dose-
response modeling was performed using a probit model with 
maximum likelihood (ML) parameter fitting. The model used 
the average reported toxicity rates and corresponding dose 
metrics reported in each included study. The average toxicity 
rate was then binned into binary outcomes to facilitate ML 
parameter fitting. Confidence intervals for dose-response 
curves were calculated using bootstrap method using random 
sampling with replacement.  
 
Results: Increased MLD was positively correlated with G3+ 
enzyme toxicity; however, the probit model fitting did not 
produce a statistically significant dose-response fit. Possible 
explanations are the sparsity of data, low incidence of 
complications, variations in baseline liver function and 
cancer type, and lack of standardization of definitions used 
for liver enzyme abnormalities. The analysis relating G2+ GI 
toxicity to RX/PTV dose showed a statistically significant 
probit model fit. Model fitting parameters were D50 of 47.7 
Gy (95% CI 43.0 - 68.8 Gy) and γ50 of 0.79 (95% CI 0.34 - 
1.25). The plot relating G3+ GI toxicity to RX/PTV dose 
demonstrated a dose response with a statistically significant 
probit model fit. Model fitting parameters were D50 of 90.2 
Gy (95% CI 67.2 - 516.4 Gy) and γ50 of 1.17 (95% CI 0.68 - 
1.69). The large D50 value of 90.2 Gy can be attributed to 
the low rates of G3+ GI toxicity. 
 
Conclusion: Our analysis shows a mean RX/PTV dose of 50 Gy 
in 3 to 6 fractions has resulted in G3+ GI toxicity risk of < 
10%. The QUANTEC liver report recommends MLD limits of 13 
Gy in 3 fractions and 18 Gy in 6 fractions for primary disease 
and 15 Gy in 3 fractions and 20 Gy in 6 fractions for 
metastases. Our analysis shows that the QUANTEC 
recommended MLD limits would likely result in acceptable 
G3+ liver enzyme toxicity risks of < 20%. 
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The group of Hans Clevers at the Hubrecht Institute 
discovered a unique marker (LGR5) for epithelial stem cells 
of the intestine (Barker et al., Nature 2007). Since then, 
LGR5 has been shown to be a marker of adult stem cells of 
multiple other tissues such as liver, pancreas, breast, and 
lung (eg: Huch et al., Nature 2013; Boj et al., Cell 2014; 
Karthaus et al., Cell 2014). With the identification of these 
stem cells and the tools to isolate them, we were able to 
develop a culture system that allowed for the virtually 
unlimited, genetically and phenotypically stable expansion of 
the cells from several animal models including human (Sato 
et al., Nature 2009, 2011; Gastroenterology 2011; Gao et al., 
Cell 2014; Boj et al., Cell 2015; Huch et al., Cell 2015; van de 
Wetering et al., in press Cell). The organoids faithfully 
represent the in vivo cells also after prolonged expansion in 
vitro. Hubrecht Organoid Technology (HUB), an entity 
founded to implement the organoid technology of the Clevers 
group, in collaboration with the Hubrecht institute, has 
generated a large collection of patient organoids from a 
